Back to results
US 12,560,610 B2Granted
Sparc assay
AssigneeNordic Bioscience A/S
InventorsStephanie Nina Kehlet, Diana Øersnes-Leeming, Morten Karsdal
Life of this patent
Estimating the term…
Abstract
The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.
Claims11
A monoclonal antibody specifically reactive with an N-terminus amino acid sequence
- (SEQ ID NO:
- 1)
- LLARDFEKNY
- comprising the complementarity-determining regions (CDRs):
- CDR-L1:
- (SEQ ID NO. 12)
- RSSQSIVHSNGNTYLE,
- CDR-L2:
- (SEQ ID NO. 13)
- KVSNRFS,
- CDR-L3:
- (SEQ ID NO. 14)
- FQGSHVPLT,
- CDR-H1:
- (SEQ ID NO. 15)
- RNAMS,
- CDR-H2:
- (SEQ ID NO. 16)
- SISTSDNTYYPDSVKG,
- and
- CDR-H3:
- (SEQ ID NO. 17)
- GFDVGAY.
20 more elements
A method of immunoassay for detecting and/or monitoring progression of lung cancer in a patient, the method comprising:
- (i) contacting a patient biofluid sample with a monoclonal antibody specifically reactive with an N-terminus amino acid sequence
- (SEQ ID NO:
- 1)
- LLARDFEKNY,
- wherein the monoclonal antibody comprises the complementarity-determining regions (CDRs):
- CDR-L1:
- (SEQ ID NO. 12)
- RSSQSIVHSNGNTYLE,
- CDR-L2:
- (SEQ ID NO. 13)
- KVSNRFS,
- CDR-L3:
- (SEQ ID NO. 14)
- FQGSHVPLT,
- CDR-H1:
- (SEQ ID NO. 15)
- RNAMS,
- CDR-H2:
- (SEQ ID NO. 16)
- SISTSDNTYYPDSVKG,
- and
- CDR-H3:
- (SEQ ID NO. 17)
- GFDVGAY,
- (ii) determining the amount of binding between said monoclonal antibody and peptides comprising said N-terminus amino acid sequence, and
- (iii) correlating said amount of binding with values associated with normal healthy subjects and/or values associated with known lung cancer severity and/or values obtained from said patient at a previous time point and/or a predetermined cut-off value.
23 more elements
A method of immunoassay for detecting and/or monitoring progression of idiopathic pulmonary fibrosis (IPF) in a patient, the method comprising:
- (i) contacting a patient biofluid sample with a monoclonal antibody specifically reactive with an N-terminus amino acid sequence
- (SEQ ID NO:
- 1)
- LLARDFEKNY,
- wherein the monoclonal antibody comprises the complementarity-determining regions (CDRs):
- CDR-L1:
- (SEQ ID NO. 12)
- RSSQSIVHSNGNTYLE,
- CDR-L2:
- (SEQ ID NO. 13)
- KVSNRFS,
- CDR-L3:
- (SEQ ID NO. 14)
- FQGSHVPLT,
- CDR-H1:
- (SEQ ID NO. 15)
- RNAMS,
- CDR-H2:
- (SEQ ID NO. 16)
- SISTSDNTYYPDSVKG,
- and
- CDR-H3:
- (SEQ ID NO. 17)
- GFDVGAY,
- (ii) determining the amount of binding between said monoclonal antibody and peptides comprising said N-terminus amino acid sequence, and
- (iii) correlating said amount of binding with values associated with normal healthy subjects and/or values associated with known IPF severity and/or values obtained from said patient at a previous time point and/or a predetermined cut-off value.
23 more elements
Dependencies are inferred from the claim text.